membranous nephropathy
Conditions
Interventions
Control Group:Glucocorticoids + Cyclophosphamide + Western medicine basic treatment
Experimental Group:Jianpi Xiusong Granules (Standardized Traditional Chinese Medicine Formulation) + Western Medicine Basic Treatment
Sponsors
Shanghai University of Traditional Chinese Medicine Affiliated Longhua Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1) Age 18-70 years 2) Confirmed primary MN (confirmed by renal biopsy) 3) Meet either of the following conditions: - Positive anti-PLA2R antibodies and ineffective after adequate first-line immunosuppressive therapy (antibodies persisting =200 RU/mL); - Negative anti-PLA2R antibodies and still presenting nephrotic syndrome after adequate first-line immunosuppressive therapy; 4) Baseline criteria: - 24-hour urine protein =3.5g; - Plasma albumin <30g/L; - eGFR =30 mL/min/1.73m²; 5) Signed informed consent.
Exclusion criteria
Exclusion criteria: 1) Secondary MN (e.g., lupus nephritis); 2) With severe conditions (NYHA III-IV heart failure, active hepatitis); 3) Within the past 6 months, used traditional Chinese medicine; 4) Pregnant/lactating women; 5) Subjects with cumulative CTX dose exceeding 10g; 6) Subjects with a history of malignancy; 7) Subjects with contraindications to glucocorticoid use;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 24-hour urinary protein quantification;anti-PLA2R antibody titer; | — |
Secondary
| Measure | Time frame |
|---|---|
| Serum Creatinine;Serum albumin;blood lipids; | — |
Countries
China
Contacts
Public ContactDeng Yueyi
Shanghai University of Traditional Chinese Medicine Affiliated Longhua Hospital
Outcome results
None listed